Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors

D Leong, PE Wu - CMAJ, 2019 - Can Med Assoc
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors Page 1 E894 CMAJ | AUGUST
12, 2019 | VOLUME 191 | ISSUE 32 © 2019 Joule Inc. or its licensors 1 Proprotein convertase …

[PDF][PDF] PCSK9 inhibitors: mechanism of action, efficacy, and safety.

EM Roth, MH Davidson - Reviews in cardiovascular medicine, 2018 - article.imrpress.com
Low-density lipoprotein (LDL) receptors on the surface of liver hepatocytes are the primary
way that humans regulate serum LDL cholesterol levels. Proprotein convertase …

PCSK9 inhibitors

P Natarajan, S Kathiresan - Cell, 2016 - cell.com
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase
subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein …

Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction

H Tavori, M Melone, S Rashid - Expert review of cardiovascular …, 2014 - Taylor & Francis
The proof of concept that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
affects cholesterol levels was first established after the demonstration that PCSK9 loss-of …

Effects of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid and lipoprotein metabolism in healthy subjects

G Reyes-Soffer, M Pavlyha, C Ngai, T Thomas… - Circulation, 2015 - Am Heart Assoc
Background: Alirocumab is a monoclonal antibody that inhibits binding of PCSK9 to LDL
receptors, decreasing their lysosomal degradation and increasing their numbers on cell …

PCSK9 inhibitors are go

A Mullard - Nature Reviews Drug Discovery, 2015 - go.gale.com
Regulators in the USA and Europe have given the green light to Sanofi and Regeneron's
alirocumab, making it the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor …

PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease

VA Bittner, RP Giugliano, EA Brinton… - Journal of clinical …, 2018 - Elsevier
The discovery of proprotein convertase subtilisin kexin-type 9 (PCSK9) and the development
of inhibitors of PCSK9 function appear to mark an epochal advance in clinical lipidology …

PCSK9 (proprotein convertase subtilisin/kexin 9) goes “DAMP”

RL Silverstein - Circulation, 2021 - Am Heart Assoc
The story began with genetic discoveries in 2003 showing that gain of function mutations in
the PCSK9 gene associated tightly with a rare form of familial hypercholesterolemia, 1 and …

Lack of cross-reactivity allergy following a switch from alirocumab to evolocumab

MD Stryker, M Kane, R Busch - Excerpts in …, 2016 - digitalcommons.cedarville.edu
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and gain-of-function
mutations were first described in 2003. The gain-of-function mutations observed were …

Counterpoint: soy protein

D Jenkins - Journal of Clinical Lipidology, 2017 - lipidjournal.com
Available proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors are human monoclonal
antibodies that produce remarkable reductions in low-density lipoprotein cholesterol (LDL …